The administration of primary prophylaxis from the first cycle, independently of the patients and chemotherapy characteristics, and of the type of G-CSF used, protected against severe neutropenia and febrile neutropenia development and was associated to higher chemotherapy dose intensity and response rate. This evidence concerns the gene CSF3 and Decreased total neutrophil count.